Trial | NCT02297867  Report issue

Title

Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis
Adipose-Derived Stem Cells (ADSCs) Injections for Liver Cirrhosis

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    6
The aim of the investigators study was to investigate the safety and efficacy of autologous ADSCs for the clinical treatment of liver cirrhosis.
One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
Study Started
Jul 13
2015
Primary Completion
Dec 18
2017
Study Completion
Mar 27
2018
Last Update
Apr 17
2018

Drug ADSCs

autologous ADSCs

  • Other names: hADSCs

ADSCs Experimental

One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.

Criteria 

Inclusion Criteria:

Liver cirrhosis investigators with age 20 to 80 years (both inclusive).
Investigators without Mandatory Communicable Disease (HBV, HCV, HIV, syphilis)
Investigators without rare disorder
Coagulation normalities
Investigators without autoimmune disorder
Investigators without Acquired Immune Deficiency Syndrome
Investigators without cancer
Investigators BMI > 15

Exclusion Criteria:

Pregnant women
Investigators with acute stroke in one month and unconsciousness
Investigators with acute myocardial infarction or acute heart failure
Investigators with serious liver dysfunction and coagulation dysfunction and ascites mild higher
Investigators with acute respiratory failure or pneumonia
Kidney Failure: BUN > 50
Anemia: Hematocrit < 25
Investigators diagnosed with liver cancer or liver metastatic carcinoma
Investigators with liver abscess
Investigators with acute Hepatitis
Investigators with acute infective
Liver cirrhosis patients with HBV or HCV
Investigators diagnosed with carcinoma and receiving treatment
Investigators with Schizophrenia or melancholia
Investigators received serious surgical operations in 3 months
Investigators unable to control hypertension (SBP > 180 mmHg, DBP > 110 mmHg) or diabetes (AC sugar > 200 mg/dl)
Others can't fit into the trial evaluate by investigator
No Results Posted